Creative Planning’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$289K Buy
94,208
+44,673
+90% +$173K ﹤0.01% 3456
2025
Q4
$203K Buy
49,535
+22,217
+81% +$110K ﹤0.01% 3543
2025
Q3
$133K Sell
27,318
-8,902
-25% -$46.8K ﹤0.01% 3618
2025
Q2
$183K Sell
36,220
-1,869
-5% -$9.18K ﹤0.01% 3255
2025
Q1
$201K Buy
38,089
+1,661
+5% +$12.1K ﹤0.01% 3068
2024
Q4
$246K Buy
+36,428
New +$245K ﹤0.01% 2824
2023
Q4
Sell
-18,287
Closed -$140K 3041
2023
Q3
$140K Buy
+18,287
New +$182K ﹤0.01% 2333

Other funds holding RXRX

Creative Planning's RXRX Position: Q1 2026 in Review

Creative Planning increased its Recursion Pharmaceuticals (RXRX) stake by 90% in Q1 2026, buying an estimated $173K and bringing the position to 94,208 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #3456.

Creative Planning first reported a position in RXRX in Q3 2023 and has held it in 7 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Creative Planning held 94,208 shares of Recursion Pharmaceuticals worth $289K as of Q1 2026.
  • Creative Planning bought 44,673 Recursion Pharmaceuticals shares in Q1 2026, an estimated $173K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3456 holding.
  • Creative Planning first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 7 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.